UTHR Q2 2017 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena

UTHRUnited Therapeutics Corporation

$24B

Q2 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$445M+7.8% YoY

Gross Profit

$426M95.7% margin

Operating Income

$89M19.9% margin

Net Income

-$56M-12.6% margin

EPS (Diluted)

$-1.25

QoQ Revenue Growth

+20.0%

Cash Flow

Operating Cash Flow

$71M

Free Cash Flow

$50M

Stock-Based Comp.

-$2M

Balance Sheet

Total Assets

$2.7B

Total Liabilities

$896M

Stockholders' Equity

$1.8B

Cash & Equivalents

$1.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$445M	$413M	+7.8%
Gross Profit	$426M	$393M	+8.4%
Operating Income	$89M	$285M	-69.0%
Net Income	-$56M	$206M	-127.2%

Revenue Segments

Remodulin

$158M35%

Adcirca

$121M27%

Tyvaso

$104M23%

Orenitram

$46M10%

Unituxin

$16M4%